Skip to content
Clinical Trials – home

Glipizide: A Comprehensive Guide for Patients

0 / 1
trials open to patients / all trials
1+
Countries

In short

Glipizide is a medication commonly used to treat type 2 diabetes. This article examines various clinical trials that have investigated the effectiveness and safety of glipizide for managing blood sugar levels in diabetic patients. The trials cover different aspects of glipizide use, including comparisons with other diabetes medications, its effects in elderly patients and those with kidney disease, and its impact on liver and heart health.

At a glance

Primary Use
Treatment of type 2 diabetes
Mechanism of Action
Stimulates pancreas to produce more insulin
Comparison Studies
Compared with newer medications like alogliptin, sitagliptin, and exenatide
Special Populations
Studied in elderly patients and those with chronic kidney disease
Key Outcomes Measured
Changes in HbA1c, fasting plasma glucose, hypoglycemia incidence
Safety Considerations
Monitoring for hypoglycemia and other adverse events
Additional Research Areas
Effects on liver fat, heart function, and intestinal microbiome

What is Glipizide?

Glipizide is a medication used to treat type 2 diabetes mellitus. It belongs to a class of drugs called sulfonylureas. Glipizide is also known by brand names such as Glucotrol and Glucotrol XL. This medication helps control blood sugar levels in people with diabetes by stimulating the pancreas to produce more insulin.

What Conditions Does Glipizide Treat?

Glipizide is primarily used to treat:

  • Type 2 Diabetes Mellitus: This is a condition where your body doesn't use insulin properly, leading to high blood sugar levels.
  • Hyperglycemia: This refers to high blood sugar levels, which is a common problem in diabetes.

In some cases, glipizide may also be used in patients with:

  • Chronic Kidney Disease: Some studies have explored its use in patients with diabetes who also have kidney problems.
  • End-Stage Renal Disease: Research has been conducted on using glipizide in diabetic patients undergoing dialysis.

How Does Glipizide Work?

Glipizide works by stimulating the pancreas to produce more insulin. Insulin is a hormone that helps your body use glucose (sugar) for energy. By increasing insulin production, glipizide helps lower blood sugar levels. This medication is part of a group of drugs called insulin secretagogues, which means they promote insulin secretion.

Dosage Forms and Administration

Glipizide comes in different forms and dosages:

  • Immediate-release tablets: These are usually taken once or twice daily, often before meals.
  • Extended-release tablets (Glucotrol XL): These are designed to release the medication slowly over time and are typically taken once daily.

The dosage can range from 2.5 mg to 20 mg per day, depending on the patient's needs and response to the medication. It's important to take glipizide exactly as prescribed by your doctor.

Effectiveness of Glipizide

Glipizide has been shown to be effective in lowering blood sugar levels in people with type 2 diabetes. Its effectiveness is often measured by changes in hemoglobin A1c (HbA1c), which is a measure of average blood sugar levels over the past 2-3 months.

Studies have shown that glipizide can significantly reduce HbA1c levels, with some patients achieving target blood sugar levels. However, the effectiveness can vary from person to person, and your doctor will monitor your response to the medication.

Potential Side Effects

Like all medications, glipizide can cause side effects. The most common and important side effect to be aware of is:

  • Hypoglycemia: This is when your blood sugar drops too low. Symptoms can include shakiness, dizziness, sweating, and confusion.

Other potential side effects may include weight gain and gastrointestinal issues. It's important to discuss any side effects you experience with your healthcare provider.

Use in Special Populations

Glipizide may be used in certain special populations, but with caution:

  • Elderly patients: Older adults may be more sensitive to the effects of glipizide and may require lower doses.
  • Patients with kidney disease: Glipizide has been studied in patients with chronic kidney disease, but close monitoring is required.
  • Patients on dialysis: Some research has explored the use of glipizide in patients with end-stage renal disease who are on dialysis.

Comparisons with Other Medications

Several studies have compared glipizide to other diabetes medications:

  • Glipizide vs. Alogliptin: A study compared these medications in elderly diabetic patients, looking at their effectiveness and safety.
  • Glipizide vs. Sitagliptin: Research has compared these drugs in patients with diabetes and end-stage renal disease.
  • Glipizide vs. Acarbose: A study looked at how these medications affect intestinal health and hormone levels in diabetic patients.

Ongoing Research

Research on glipizide is ongoing, with studies exploring various aspects of its use:

  • Genetic factors: Some research is looking at how genetic variations might affect how people respond to glipizide.
  • Combination therapies: Studies are exploring how glipizide works when combined with other diabetes medications.
  • Effects on heart health: Researchers are investigating how glipizide might affect heart function and fat around the heart.

These ongoing studies help doctors better understand how to use glipizide effectively and safely in different patient populations.

Questions people often ask

Conditions where Glipizide is being studied

Each condition opens its own overview and trial list

Trials with Glipizide

Recruiting trials first

See all 1 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).